phase readout
saveNCT03961009: Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in PID Patients
COMPLETEDupdated 36m ago
community read0 votes
Sponsor: Kedrion S.p.A.. Phase: PHASE3. Conditions: Primary Immunodeficiency Disease
view source ↗
comments(0)
5-min edit window · permanent after that